Innovative imaging VerAvanti is developing the Scanning Fiber Endoscope to advance intravascular visualization, enabling earlier detection and more confident interventions across cardiovascular, neurovascular, and peripheral applications, which presents opportunities to target hospitals and interventional centers focused on early disease characterization.

Clinical differentiation The technology aims to provide forward-looking, high-resolution vessel-level visualization beyond traditional imaging. This positions VerAvanti to engage health systems seeking cutting-edge diagnostic tools to improve risk assessment and patient outcomes.

Funding traction With a Series A of 31.5 million and total funding around 38 million, the company demonstrates financial backing and growth potential, which can be leveraged in conversations about scaling clinical adoption, pilot programs, and long-term partnerships.

Recognition opportunity Being named a finalist for Innovation of the Year at the 2026 GeekWire Awards enhances credibility and can be used to approach potential customers, investors, and collaborators with third-party validation.

Growth signals Revenue is in the low to mid single-digit millions with a lean employee base, suggesting a focus on strategic partnerships, pilot deployments, and channel collaborations to accelerate market entry and revenue expansion.